Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Novartis ADR representing 1 Ord Shs NVS

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory... see more

NYSE:NVS - Post Discussion

Novartis ADR representing 1 Ord Shs > ONE DRUG PILL WIPES OUT COVID 19!
View:
Post by zeropointenergy on Oct 06, 2021 7:37am

ONE DRUG PILL WIPES OUT COVID 19!

Sep 27, 2021 · By September 12, 2021, Livemint reported that 34 districts were declared COVID-free or had no active cases. Only 14 new cases were recorded in

Oct 03, 2021 · INDIA GOVT. DECLARES MOST POPULATED STATE OFFICIALLY COVID FREE AFTER WIDESPREAD USE OF IVERMECTIN. VIDEO: Well well.

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities